Cogstate’s computerized battery of rapid, reliable, simple and sensitive tests measure the cognitive domains affected by mild cognitive impairment and pre-clinical AD: processing speed, attention, visual learning and working memory.
The construct validity of each test for cognitive impairment in pre-clinical AD as well as the sensitivity of these tests to change in cognition has been demonstrated in the scientific literature. The tests have also been shown to be valid for use in different cultures and language groups with comparative/normative data available for both clinical samples and healthy controls. Study teams wishing to measure all or a subset of these domains can choose the tests that best suit their specific research questions. Each of the tests have been utilized previously in drug trials and maintain excellent reliability across repeated testing and cross-sectional research designs.
The Detection Test uses a simple reaction time paradigm to measure processing speed.
Cognitive Domain Measured: Psychomotor Function
The Identification Test uses a choice reaction time paradigm to measure attention.
Cognitive Domain Measured: Attention
One Card Learning Test
The One Card Learning Test uses a pattern separation paradigm to measure visual memory.
Cognitive Domain Measured: Visual Learning
One Back Test
The One Back Test uses an n-back paradigm to measure working memory.
Cognitive Domain Measured: Working Memory
|Length:||Between 5-15 minutes
(depending on the number of tests included in the battery*)
|Data Processing and Scoring:||Automated|
|Culture and Language Neutral:||Yes|
Lim, Y. Y., Maruff, P., Pietrzak, R. H., Ellis, K. A., Darby, D., Ames, D., … Rowe, C. C. (2014). Aβ and cognitive change: Examining the preclinical and prodromal stages of Alzheimer’s disease. Alzheimer’s & Dementia, 10(6), 743-751. doi: http://dx.doi.org/10.1016/j.jalz.2013.11.005
Lim, Y. Y., Villemagne, V. L., Pietrzak, R. H., Ames, D., Ellis, K. A., Harrington, K., … Maruff, P. (2014). APOE ε4 moderates amyloid-related memory decline in preclinical Alzheimer’s disease. Neurobiology of Aging, 11. doi: 10.1016/j.neurobiolaging.2014.12.008
Lim, Y. Y., Ellis, K. A., Harrington, K., Pietrzak, R. H., Gale, J., Ames, D., Bush, A. I., Darby, D., Martins, R. N., Masters, C. L., Rowe, C. C., Savage, G., Szoeke, C., Villemagne, V. L., Maruff P. (2013) Cognitive decline in adults with amnestic mild cognitive impairment and high amyloid-β: prodromal Alzheimer’s disease? Journal of Alzheimer’s Disease: 33 (4); 1167-76
Lim, Y. Y., Maruff, P., Pietrzak, R. H., Ames, D., Ellis, K. a, Harrington, K., … Rowe, C. C. (2014). Effect of amyloid on memory and non-memory decline from preclinical to clinical Alzheimer’s disease. Brain : a journal of neurology, 137(Pt 1), 221–31. doi:10.1093/brain/awt286
Lim, Y. Y., Villemangne, V. L., Laws, S. M., Pietrzak, R. H., Snyder, P. J., Ames, D., … Maruff, P. (2014). APOE and BDNF polymorphisms moderate amyloid β-related cognitive decline in preclinical Alzheimer’s disease. Molecular Psychiatry. doi: 10.1038/mp.2014.123